ArticleInternational journal of molecular sciences2025
The Prognostic Value of CIP2A and Its Association with CD31, E-Cadherin, and pAMPK in Lung Cancer.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein promoting tumor progression via multiple pathways. Its prognostic significance in lung cancer remains unclear. We analyzed tumor samples from 53 patients with lung cancer undergoing curative surgical resection without prior chemotherapy or radiotherapy. Immunohistochemical staining and H-score quantification were performed to assess CIP2A and related protein expression. Patients were stratified based on CIP2A expression (cutoff value = 218.33). Kaplan-Meier survival analysis produced curves and log-rank tests. Correlations with clinicopathological and molecular markers were assessed. High CIP2A expression was significantly associated with poorer survival (log-rank,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.